Long

BVXV innovative COVID-19 nanosized antibodies

BiondVax has signed definitive agreements with the Max Planck Society and the University Medical Center Göttingen to enter into a strategic collaboration for the development and commercialization of innovative COVID-19 nanosized antibodies (NanoAbs).
NanoAbs exhibited in-vitro neutralization of all COVID-19 variants of concern including Delta, and based on in-silico studies, Omicron, at significantly lower dose levels than existing antibody treatments.

i know that this is an early stage, but today they announced also that the Former CFO of GSK's Global Vaccines Business Mr. Jay Green Joins BiondVax's Board of Directors.

just to make an idea, GSK has a Market Cap of 111Bil and Jay Green went to a company that has a mk cap of 35Mil.

They also had a public offering at the price of $2.36.

52 Week Range 1.36 - 7.22

My price target is $6
biondvaxbuyBVXVCoronavirus (COVID-19)Fundamental AnalysisGSKTechnical IndicatorsnanoabssignalsignalsTrend Analysis

Also on:

Disclaimer